Narval

Narval develops a new class of antibody therapeutics based on synthetic proteins engineered to mimic the function of natural antibodies. These proprietary 'Nanolilin' proteins are designed for delivery through mucosal tissues and skin, targeting diseases in organs such as the eyes, lungs, and skin. The company's platform aims to overcome the limitations of traditional monoclonal antibodies, which are typically administered via injection and struggle to reach these specific tissues effectively. By enabling non-invasive, localized drug delivery, Narval's approach could offer treatments for a range of inflammatory and other diseases affecting mucosal surfaces.

The company was founded in May 2024 by serial biotech entrepreneur Dr. Christophe Mas, who serves as the CEO. Dr. Mas brings extensive experience from his previous ventures, including the co-founding of T-Liance, a company specializing in T-cell analysis that was later acquired, and leading technological innovation at HORIBA Medical for over a decade. This background in diagnostics and therapeutic development informs Narval's strategy. The company is currently in a pre-seed stage, focusing on advancing its technology platform towards preclinical development.

Keywords: antibody therapeutics, synthetic proteins, mucosal delivery, localized treatment, nanolin proteins, ophthalmology, pulmonology, dermatology, biopharmaceuticals, pre-seed biotech